The approval covers patients aged six years and older, addressing a significant gap in pediatric dermatological care. To accommodate varying patient needs, the company is introducing a new 55 mg pre-filled syringe specifically designed for children weighing less than 40 kg, or roughly 88 lbs. Older or heavier pediatric patients will utilize the existing 150 mg pre-filled syringe and pen formats already established in adult treatment protocols.

Beyond this new pediatric indication, Skyrizi remains a foundational asset in AbbVie’s immunology portfolio. The drug is currently prescribed for adults battling moderate-to-severe plaque psoriasis, active psoriatic arthritis, Crohn's disease, and ulcerative colitis. By extending the drug’s reach to younger patients, AbbVie aims to standardize treatment pathways across age groups, provided the patients meet the specific weight-based dosing requirements.